Logo

American Heart Association

  2
  0


Final ID:

The Trouble with ESUS: What do the studies tell us? Where do we do from here?

  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
  • Messe, Steven  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now) | Steven Messe: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available